In summary, the Company believes that the use of the current design adequately addresses the objective to demonstrate the non-inferiority of immune response to the 2- dose schedule in 9 to 14 year-old females compared to the 18 to 25 year old women in which efficacy was demonstrated and thereby will allow to bridge the efficacy to this alternative schedule.